Department of Internal Medicine (Nephrology), Leiden University Medical Center, Leiden, Netherlands.
Front Immunol. 2020 Mar 12;11:359. doi: 10.3389/fimmu.2020.00359. eCollection 2020.
Worldwide over 40% of patients receiving renal replacement therapy (RRT) are aged 65 years or older, a number that is still increasing. Renal transplantation is the preferred RRT, providing substantial survival benefit over those remaining on dialysis, including the elderly. Only 3% of patients aged 65 years or older accepted on the waiting list actually received a kidney transplant offer within the Eurotransplant allocation region. To increase the chance for elderly to receive a timely kidney transplant, the Eurotransplant Senior Program was introduced. The ESP supports local allocation of older kidneys to older donors in order to decrease cold ischemia time, while disregarding former exchange principles based on matching for HLA antigens. As a consequence, more elderly received a kidney transplant and a relative higher incidence of acute rejection resulted in additional courses of high steroids and/or depleting antibody therapy. Since death with a functioning graft due to infections is the dominant reason of graft loss in elderly, more intense clinical immunosuppression to prevent or treat acute rejection is not a very attractive option. Therefore in elderly kidney transplant candidates, we advocate reintroduction of minimal histocompatibility criteria (i.e., HLA-DR matching) followed by age-matching with mandatory local/regional allocation to also facilitate short cold ischemia.
全球超过 40%接受肾脏替代治疗(RRT)的患者年龄在 65 岁或以上,这一数字仍在增加。肾移植是首选的 RRT,与仍在透析的患者(包括老年人)相比,肾移植提供了显著的生存获益。在 Eurotransplant 分配区域,只有 3%的 65 岁或以上的等候名单上的患者实际上获得了肾移植的机会。为了增加老年患者及时接受肾移植的机会,引入了 Eurotransplant 老年计划(ESP)。ESP 支持将老年供者的老年肾脏在本地分配,以减少冷缺血时间,同时不考虑以前基于 HLA 抗原匹配的交换原则。因此,更多的老年患者接受了肾移植,而急性排斥反应的相对较高发生率导致了更高剂量的类固醇和/或耗竭抗体治疗。由于感染导致的带功能移植物死亡是老年患者移植物丢失的主要原因,因此,进行更强烈的临床免疫抑制以预防或治疗急性排斥反应并不是一个非常有吸引力的选择。因此,对于老年肾移植候选者,我们主张重新引入最小的组织相容性标准(即 HLA-DR 匹配),然后进行年龄匹配,并强制进行本地/区域分配,以促进短冷缺血。